Literature DB >> 11095412

TYRP2-mediated resistance to cis-diamminedichloroplatinum (II) in human melanoma cells is independent of tyrosinase and TYRP1 expression and melanin content.

B J Pak1, Q Li, R S Kerbel, Y Ben-David.   

Abstract

Tyrosinase-related protein-2 (TYRP2) is a melanocyte-specific enzyme that catalyses the non-decarboxylative tautomerization of L-dopachrome to 5,6-dihydroxyindole-2-carboxylic acid (DHICA) in the melanin biosynthetic pathway. We have recently demonstrated that the constitutive expression of TYRP2 in human melanoma cells positively correlates with cis-diamminedichloroplatinum (II) (CDDP) resistance, and that the ectopic expression of TYRP2 in CDDP-sensitive cells rendered them more resistant to CDDP treatment. Here, we demonstrate that this correlation between constitutive TYRP2 expression and CDDP resistance applies to a panel of distinct human melanoma cell lines obtained from patients with melanoma at various stages of disease progression. We further show that CDDP resistance correlates only with TYRP2 expression and is associated neither with tyrosinase and TYRP1 expression, nor with cellular melanin content. Together, these results further support the notion that TYRP2 is a novel mediator of CDDP resistance in melanoma cells and suggest that this function of TYRP2 is independent of cellular melanin content and of the other regulatory enzymes of the melanogenic pathway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095412     DOI: 10.1097/00008390-200010000-00013

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  7 in total

1.  Cross-talk between Dopachrome Tautomerase and Caveolin-1 Is Melanoma Cell Phenotype-specific and Potentially Involved in Tumor Progression.

Authors:  Ioana L Popa; Adina L Milac; Livia E Sima; Petruta R Alexandru; Florin Pastrama; Cristian V A Munteanu; Gabriela Negroiu
Journal:  J Biol Chem       Date:  2016-04-06       Impact factor: 5.157

2.  Purification and N-glycosylation analysis of melanoma antigen dopachrome tautomerase.

Authors:  Christopher J Vavricka; Keith W Ray; Bruce M Christensen; Jianyong Li
Journal:  Protein J       Date:  2010-04       Impact factor: 2.371

3.  Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas.

Authors:  Kevin G Chen; Julio C Valencia; Barry Lai; Guofeng Zhang; Jill K Paterson; François Rouzaud; Werner Berens; Stephen M Wincovitch; Susan H Garfield; Richard D Leapman; Vincent J Hearing; Michael M Gottesman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-15       Impact factor: 11.205

4.  Influence of melanosome dynamics on melanoma drug sensitivity.

Authors:  Kevin G Chen; Richard D Leapman; Guofeng Zhang; Barry Lai; Julio C Valencia; Carol O Cardarelli; Wilfred D Vieira; Vincent J Hearing; Michael M Gottesman
Journal:  J Natl Cancer Inst       Date:  2009-08-24       Impact factor: 13.506

Review 5.  Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma.

Authors:  Kevin G Chen; Julio C Valencia; Jean-Pierre Gillet; Vincent J Hearing; Michael M Gottesman
Journal:  Pigment Cell Melanoma Res       Date:  2009-08-29       Impact factor: 4.693

6.  The Role of DCT in HPV16 Infection of HaCaTs.

Authors:  Pınar Aksoy; Patricio I Meneses
Journal:  PLoS One       Date:  2017-01-17       Impact factor: 3.240

7.  Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma.

Authors:  B Keenen; H Qi; S V Saladi; M Yeung; I L de la Serna
Journal:  Oncogene       Date:  2009-09-28       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.